(338 days)
No
The description focuses on the mechanical aspects of a stent and delivery system, with no mention of AI or ML in the device description, intended use, or performance studies.
Yes
The device is intended for maintaining esophageal luminal patency in esophageal strictures caused by malignant tumors and occlusion of concurrent esophageal fistula, which directly addresses a medical condition and provides a therapy.
No
The device is a stent system intended for maintaining esophageal luminal patency, which is a treatment, not a diagnostic function.
No
The device description clearly states it is a "self-expanding metallic stent" and a "flexible delivery catheter preloaded with an expandable stent," indicating it is a physical medical device with hardware components.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- IVD Definition: In vitro diagnostics are tests performed on samples taken from the human body, such as blood, urine, or tissue, to detect diseases, conditions, or infections.
- Device Function: The Ultraflex™ Esophageal NG Stent System is a medical device designed to be implanted within the esophagus to maintain luminal patency. It is a physical device used for treatment, not a test performed on a sample outside the body.
- Intended Use: The intended use clearly states it's for maintaining esophageal luminal patency in strictures caused by malignant tumors and, for the covered version, occluding fistulas. This is a therapeutic intervention, not a diagnostic test.
- Device Description: The description details a self-expanding metallic stent and a delivery system, consistent with an implantable medical device.
- Lack of IVD Characteristics: There is no mention of analyzing biological samples, detecting biomarkers, or providing diagnostic information based on laboratory testing.
Therefore, the Ultraflex™ Esophageal NG Stent System falls under the category of an implantable medical device used for therapeutic purposes, not an in vitro diagnostic.
N/A
Intended Use / Indications for Use
Ultraflex™ Esophageal NG Stent System (non-covered) is intended for maintaining esophageal luminal patency in esophageal strictures caused by intrinsic malignant tumors only.
Ultraflex™ Esophageal NG Stent System (covered) is intended for maintaining esophageal luminal patency in esophageal strictures caused by intrinsic and/or extrinsic malignant turnors only, and occlusion of concurrent esophageal fistula.
Product codes
ESW
Device Description
The proposed Ultraflex Esophageal NG Stent System allows for the placement of a self-expanding metallic stent within the esophagus. The systems consist of a flexible delivery catheter preloaded with an expandable stent. The stent is offered either bare or covered and with either a proximal release or distal release delivery system. The stent may be placed fluoroscopically using radiopaque markers as a guide or endoscopically using the visual marker on the delivery catheter. The proposed device incorporates an updated Magnetic Resonance (MR) Conditional statement in the Directions for Use.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Esophagus
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Magnetic Resonance testing has been performed for the Ultraflex™ Esophageal NG Stent. The Directions for Use meet the requirements for MR Conditional labeling per ASTM standard F 2503-08.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 878.3610 Esophageal prosthesis.
(a)
Identification. An esophageal prosthesis is a rigid, flexible, or expandable tubular device made of a plastic, metal, or polymeric material that is intended to be implanted to restore the structure and/or function of the esophagus. The metal esophageal prosthesis may be uncovered or covered with a polymeric material. This device may also include a device delivery system.(b)
Classification. Class II. The special control for this device is FDA's “Guidance for the Content of Premarket Notification Submissions for Esophageal and Tracheal Prostheses.”
0
SECTION 5 510(k) SUMMARY
510(k) SUMMARY
1. Submitter:
Boston Scientific Corporation 100 Boston Scientific Way Marlborough, MA 01752 Telephone: 508-683-4560 Fax: 508-683-5939
Contact: Janis F. Taranto, M.S., RAC Regulatory Affairs Specialist Date Prepared: December 31, 2012
DEC 0 6 2013
2. Proposed Device:
Trade Name: Ultraflex™ Esophageal NG Stent System Classification Name: Esophageal Prosthesis Regulation Number: 878.3610 Product Code: ESW Classification: Class II
3. Predicate Device:
Trade Name: Ultratlex™ Esophageal NG Stent System Manufacturer and Clearance Number: Boston Scientific Corporation, K091816, K120983 Classification Name: Esophageal Prosthesis Regulation Number: 878.3610 Product Code: ESW Classification: Class II
Trade Name: Ultraflex™ Tracheobronchial Stent System Manufacturer and Clearance Number: Boston Scientific Corporation, K121048 Classification Name: Prosthesis, Tracheal, Expandable Regulation Number: 878.3720 Product Code: JCT Classification: Class II
4. Proposed Device Description:
The proposed Ultraflex Esophageal NG Stent System allows for the placement of a self-expanding metallic stent within the esophagus. The systems consist of a flexible delivery catheter preloaded with an expandable stent. The stent is offered either bare or covered and with either a proximal release or distal release delivery system. The stent may be placed fluoroscopically using radiopaque markers as a guide or endoscopically using the visual marker on the delivery catheter. The proposed device incorporates an updated Magnetic Resonance (MR) Conditional statement in the Directions for Use.
1
5. Indications for Use:
Ultraflex™ Esophageal NG Stent System (non-covered) is intended for maintaining esophageal luminal patency in esophageal strictures caused by intrinsic malignant tumors only.
Ultraflex™ Esophageal NG Stent System (covered) is intended for maintaining esophageal luminal patency in esophageal strictures caused by intrinsic and/or extrinsic malignant turnors only, and occlusion of concurrent esophageal fistula.
6. Technological Characteristics:
The proposed Ultraflex™ Esophageal NG Stent System is identical in design and materials to the predicate Ultraflex™ Esophageal NG Stent System (K091816, K120983) while incorporating an updated MR Conditional statement in the Directions for Use stating compatibility with 1.5 and 3.0 Tesla use. This MR Conditional statement is identical to the statement used in the Ultrallex™ Tracheobronchial Stent System (K121048) DFU.
7. Performance Data:
Magnetic Resonance testing has been performed for the Ultraflex™ Esophageal NG Stent. The Directions for Use meet the requirements for MR Conditional labeling per ASTM standard F 2503-08.
8. Conclusion:
Boston Scientific Corporation has demonstrated that the proposed Ultraflex™ Esophageal NG Stent System with the minor labeling change to update the MR Conditional statement in the DFU, is substantially equivalent to Boston Scientific Corporation's currently marketed Ultraflex™ Esophageal NG Stent System (K091816. K120983) and UltraflexTM Tracheobronchial Stent System (K121048).
2
Image /page/2/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo features a stylized depiction of an eagle or bird-like figure with outstretched wings. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular fashion around the bird-like figure.
Public I lealth Service
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring. MD 20993-0002
December 6, 2013
Boston Scientific Corporation Janis F. Taranto, M.S., RAC Senior Regulatory Affairs Specialist 100 Boston Scientific Way, M-11 Marlborough, MA 01752
Re: K130004
Trade/Device Name: Ultraflex™ Esophageal NG Stent System Regulation Number: 21 CFR§ 878.3610 Regulation Name: Esophageal prosthesis Regulatory Class: II Product Code: ESW Dated: November 7, 2013 Received: November 8, 2013
Dear Janis F. Taranto.
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA), You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration. Ilisting of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of
3
Page 2 - Janis F. Taranto, M.S., RAC
medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely yours,
Benjamin R. Fisher -S
Benjamin R. Fisher, Ph.D. Director Division of Reproductive, Gastro-Renal, and Urological Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
4
SECTION 4 INDICATIONS FOR USE STATEMENT
510(k) Number (if known): K130004
Device Name:
て、どちらないから、「トバ
Ultraflex™ Esophageal NG Stent System
Indications for Use:
Ultraflex™ Esophageal NG Stent System (covered) is intended for maintaining esophageal luminal patency in esophageal strictures caused by intrinsic and/or extrinsic malignant turnors only, and occlusion of concurrent esophageal fistula.
Prescription Use X (Part 21 CFR 801 Subpart D) AND/OR
Over-The-Counter Use (21 CFR 807 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Benjamin R. Fisher -S 2013.12.09 20:05:46 -05'00'
510(k) Premarket Notification, Ultraflex™ Esophageal NG Stent System
5
SECTION 4 INDICATIONS FOR USE STATEMENT
510(k) Number (if known): KI30004
Device Name:
Ultraflex™ Esophageal NG Stent System
Indications for Use:
Ultraflex™ Esophageal NG Stent System (non-covered) is intended for maintaining esophageal luminal patency in esophageal strictures caused by intrinsic and/or extrinsic malignant tumors only.
· AND/OR Prescription Use × (Part 21 CFR 801 Subpart D)
Over-The-Counter Use (21 CFR 807 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
.
Concurrence of CDRH, Office of Device Evaluation (ODE)
Benjamin R. Fisher -S 2013.12.09 20:06:40 -05'00'
510(k) Premarket Notification, Ultraflex™ Esophageal NG Stent System